Cure My Disease

Don't miss your cure!

 Log in / Sign up

Timing is everything: new study seeks optimal moment for dialysis in cancer-related kidney failure

NCT ID NCT06889974

Knowledge-focused Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study examines whether starting kidney dialysis early or later improves outcomes for patients with tumor lysis syndrome, a complication of cancer treatment that can cause acute kidney injury. Researchers will review data from 800 adults treated in ICUs between 2013 and 2023. The goal is to see which timing leads to better kidney function after 30 days.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors know the best time to start dialysis for kidney injury from tumor lysis syndrome, potentially improving recovery.
What could go wrong
This is an observational study, not a controlled trial, so results may show patterns but not prove cause and effect. It also looks at past data, which may have limitations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 800 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This is a retrospective, multicenter cohort study conducted across several intensive care units (ICUs) in France. Data will be collected retrospectively from patient records and analyzed to assess the impact of early versus delayed RRT initiation on clinical outcomes in patients with TLS-induced AKI.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged ≥18 years. * Hospitalized in the ICU between January 1, 2013, and December 31, 2023. * Diagnosed with a hematologic malignancy or solid tumor requiring chemotherapy. * Diagnosed with TLS based on the presence of two or more biochemical criteria (e.g., hyperkalemia, hyperphosphatemia, hyperuricemia, hypocalcemia) within 3 days before or 7 days after chemotherapy initiation. Exclusion Criteria: * Patient or family opposition to data collection for research purposes. * Incomplete medical records that preclude data extraction.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Renal replacement therapy for acute kidney injury in icu are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute kidney injury tumor lysis syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Renal replacement therapy for acute kidney injury in icu

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    8 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CH de Pau

    RECRUITING

    Pau, France

  • CHR d'Orléans

    RECRUITING

    Orléans, France

  • CHU Dupuytren 1

    WITHDRAWN

    Limoges, France

  • CHU d'Angers

    WITHDRAWN

    Angers, France

  • Centre Urgences-Réanimations

    RECRUITING

    Rennes, France

  • Hôpital Bretonneau

    RECRUITING

    Tours, France

  • Hôpital Pellegrin

    RECRUITING

    Bordeaux, France

  • Hôpital la cavale blanche

    RECRUITING

    Brest, France

  • Hôtel-Dieu

    RECRUITING

    Nantes, France

  • IUCT-O Hopital Purpan

    RECRUITING

    Toulouse, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.